Sugawara K, et al. - In this cross-sectional study involving T2DM patients treated (Met group, n = 122) or not treated (control group, n = 63) with metformin, researchers intended to determine if there is an association between metformin use and VB₁₂ status in these individuals. According to findings, homocysteine levels, as well as the level of VB₁₂, hemoglobin concentration, and mean corpuscular volume, did not vary significantly between the control and metformin groups treated. Findings suggested a positive and negative association of serum homocysteine and VB₁₂ levels with the daily dose of metformin, respectively. During metformin treatment, the risk of VB₁₂ deficiency seems to be low in Japanese T2DM patients. High doses of metformin, however, could lead to a moderate decrease in circulating VB₁₂ levels as well as anemia in elderly people.